Elotuzumab |
| Katalog-Nr.GC64565 |
Elotuzumab ist ein monoklonaler AntikÖrper, der gegen den SLAMF7-Rezeptor gerichtet ist. Elotuzumab hat keine signifikante AntimyelomaktivitÄt, wenn es als Monotherapie bei rezidiviertem oder refraktÄrem multiplem Myelom (RRMM) verabreicht wird. Elotuzumab fÜhrt zu einem verbesserten Ansprechen und Ergebnis, wenn es mit anderen Antimyelom-Wirkstoffen kombiniert wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 915296-00-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents[1].
[1]. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *